Navigation Links
KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results
Date:8/11/2008

in the meaning of the United States Private Securities Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include assumptions concerning KV's operations, future results and prospects. Such statements may be identified by the use of words like "plans", "expect", "aim", "believe", "projects", "anticipates", "commit", "intend", "estimate", "will", "should", "could" and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, including without limitation, statements about the Company's strategy for growth, product development, product launches, regulatory approvals, market position, market share increases, acquisitions, revenues, expenditures and other financial results, and expectations and beliefs pertaining to the announced Audit Committee inquiry or any allegations of misconduct that are the subject of such inquiry, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, KV provides the following cautionary statements identifying important economic, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (5) new product development and launch, including the possibility that any product launch may be delayed or tha
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , ... July 29, 2015 , ... ... increasingly aware of the impact drinking and substance abuse is having on lost ... loss is tagged in the billions per year. [1] Will Wesch, Director of ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... health inequities. Since 2012, Massachusetts law has provided legal protections against discrimination on ... the law does not protect against discrimination based on gender identity in places ...
(Date:7/29/2015)... ... ... According to the The Media Post on July 9th teenagers ... medicinal use are more likely to abuse the substance. A recent study conducted by ... beneficial are more apt to use the substance, as opposed to their peers who ...
(Date:7/29/2015)... , ... July 29, 2015 , ... Potomac Pilates, an ... changing its name to Rock the Reformer ® by Potomac Pilates. On Thursday, ... http://www.RockTheReformer.com . Rock the Reformer ® by Potomac Pilates will continue to offer the ...
(Date:7/29/2015)... ... July 29, 2015 , ... Join Luz Delia Gerber and ... believes that Well-Being begins with understanding how the body actually works. A state of ... within. Guests will receive tips on how to forge this new relationship with their ...
Breaking Medicine News(10 mins):Health News:Workplace Trouble: Survey Reveals Sharp Escalation in Restaurant/Food Service Employee Drug Abuse 2Health News:Workplace Trouble: Survey Reveals Sharp Escalation in Restaurant/Food Service Employee Drug Abuse 3Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 2Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 3Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 3Health News:Same Great Pilates Studio, New Brand - Rock the Reformer 2Health News:Pampering and Empowerment Abound at Final Event in Luz Delia Gerber’s Book Unveiling 2
... HACKETTSTOWN, NJ (March 20, 2008) V Daily consumption of ... sterols and cocoa flavanols may affect cardiovascular risk by ... to a new study published in the Journal of ... from the University of Illinois and Mars, Incorporated found ...
... found standard mound might raise risk of stress injuries ... of a pitcher,s mound can influence the risk of ... by the head team physician for the Milwaukee Brewers. ... Baseball organizations and Milwaukee-area NCAA Division I-A college teams. ...
... JOSEPH, Mich., March 26 GeneGo, Inc., ... the release of MetaMiner,Cystic Fibrosis, a first ... to help advance drug discovery for cystic ... tool will,provide the cystic fibrosis research community ...
... /Xinhua-PRNewswire-FirstCall/ -- China Yingxia,International, Inc. (OTC Bulletin ... industry engaged in the development, manufacture and,distribution ... care products in China, today announced that ... Yingxia, will host a conference call to ...
... 26 Three years ago, Leverage,Life began offering an ... Hotline program has proven to be a much-needed,benefit for ... that by 2012 the growth of the,workforce will be ... decline by nearly,three million, or 6.8%, and workers over ...
... Caregivers Say Their Children Help Care for Loved Ones With ... ... from the third annual,Alzheimer,s Foundation of America (AFA) ICAN: Investigating Caregivers,Attitudes ... Most "sandwich caregivers" -- the parents or guardians of,children under 21 ...
Cached Medicine News:Health News:New study suggests that specially-formulated 2Health News:New study suggests that specially-formulated 3Health News:Height of Pitcher's Mound Can Strain Shoulders 2Health News:GeneGo Rolls out MetaMiner Cystic Fibrosis - the First Disease-Specific Software Platform to Advance Drug Discovery 2Health News:GeneGo Rolls out MetaMiner Cystic Fibrosis - the First Disease-Specific Software Platform to Advance Drug Discovery 3Health News:China Yingxia International Announces 2007 Fourth Quarter and Full Year Financial Results Conference Call 2Health News:Leverage Life's Homework Hotline Is a Resounding Success! 2Health News:New Alzheimer's Disease Survey Reveals Children of Sandwich Caregivers Assist With Loved Ones' Care 2Health News:New Alzheimer's Disease Survey Reveals Children of Sandwich Caregivers Assist With Loved Ones' Care 3Health News:New Alzheimer's Disease Survey Reveals Children of Sandwich Caregivers Assist With Loved Ones' Care 4Health News:New Alzheimer's Disease Survey Reveals Children of Sandwich Caregivers Assist With Loved Ones' Care 5
(Date:7/29/2015)... , July 30, 2015 ... Guidance   for ... Core Earnings and Core ... Highlights of Q1 results  ... Underlying core earnings and underlying core EPS were flat, year-to-year , ...
(Date:7/29/2015)... PLEASANTON, Calif. , July 30, 2015 ... it has submitted the cobas® EGFR Mutation Test ... Food and Drug Administration (FDA), as a companion ... for non-small cell lung cancer patients with an ... non-small cell lung cancer who have adenocarcinoma with ...
(Date:7/29/2015)... 2015  Astellas today announced topline results from ... and safety of intravenous (IV) and oral isavuconazole, ... for adults with candidemia and other invasive ... that the trial did not meet its primary ... isavuconazole-treated patients at the end of IV therapy ...
Breaking Medicine Technology:Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 2Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 3Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 4Takeda Reports 1st Quarter Results of FY2015 with Underlying Revenue Growth of +6.1% 5Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 2Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5
... 2012 GoodRx today announced that ... that provides consumers with accurate drug prices from virtually every ... and free iphone app , allows consumers to compare ... find discounts, free coupons and savings tips. ...
... Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products to treat voiding dysfunctions, today announced the first ... the United Kingdom. This large multi-center, placebo-controlled ... 20 centers across the UK. Using Uroplasty,s minimally-invasive Urgent® ...
Cached Medicine Technology:GoodRx™ Brings Price Transparency to Prescription Drugs 2GoodRx™ Brings Price Transparency to Prescription Drugs 3GoodRx™ Brings Price Transparency to Prescription Drugs 4Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC 2Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC 3
For newly born children 10 mm internal diameter of the cornea part. Designed to work with argon/YAG Lasers....
For use with Slitlamps which have a smaller distance between the eye and the reduction prism than the Haag-Streit 900. Designed to work with argon/YAG Lasers....
... EyeCap is a Windows-based image capture and ... colour, red-free, fluorescent and ICG Angiography images. ... and can also obtain images from any ... output. EyeCap FA has all the features ...
... EyeCap is a Windows-based image capture and ... colour, red-free, fluorescent and ICG Angiography images. ... and can also obtain images from any ... output. EyeCap RI captures high quality colour ...
Medicine Products: